Drug resistance in HIV patients with virological failure or slow virological response to antiretroviral therapy in Ethiopia

[1]  M. Belay,et al.  Adherence to Antiretroviral Therapy and associated factors among HIV infected children in Ethiopia: unannounced home-based pill count versus caregivers’ report , 2013, BMC Pediatrics.

[2]  J. H. van de Wijgert,et al.  Low Primary and Secondary HIV Drug-Resistance after 12 Months of Antiretroviral Therapy in Human Immune-Deficiency Virus Type 1 (HIV-1)-Infected Individuals from Kigali, Rwanda , 2013, PloS one.

[3]  L. Torian,et al.  Transmitted Antiretroviral Drug Resistance in New York State, 2006-2008: Results from a New Surveillance System , 2012, PloS one.

[4]  S. Hammer,et al.  Update on World Health Organization HIV drug resistance prevention and assessment strategy: 2004-2011. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  F. Wit,et al.  Effect of pretreatment HIV-1 drug resistance on immunological, virological, and drug-resistance outcomes of first-line antiretroviral treatment in sub-Saharan Africa: a multicentre cohort study. , 2012, The Lancet. Infectious diseases.

[6]  J. Gonzalez,et al.  Virological failure rates and HIV-1 drug resistance patterns in patients on first-line antiretroviral treatment in semirural and rural Gabon , 2012, Journal of the International AIDS Society.

[7]  J. Lundgren,et al.  The rate of accumulation of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance in patients kept on a virologically failing regimen containing an NNRTI * , 2011, HIV medicine.

[8]  David Dunn,et al.  Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. , 2011, The Lancet. Infectious diseases.

[9]  M. Fowler,et al.  HIV-1 Drug Resistance Emergence among Breastfeeding Infants Born to HIV-Infected Mothers during a Single-Arm Trial of Triple-Antiretroviral Prophylaxis for Prevention of Mother-To-Child Transmission: A Secondary Analysis , 2011, PLoS medicine.

[10]  V. Calvez,et al.  Increasing prevalence of transmitted drug resistance mutations and non-B subtype circulation in antiretroviral-naive chronically HIV-infected patients from 2001 to 2006/2007 in France. , 2010, The Journal of antimicrobial chemotherapy.

[11]  A. Wensing,et al.  Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review. , 2010, The Lancet. Infectious diseases.

[12]  N. Obel,et al.  The Incidence Rate of HIV Type-1 drug Resistance in Patients on Antiretroviral Therapy: A Nationwide Population-Based Danish Cohort Study 1999–2005 , 2009, Antiviral therapy.

[13]  C. Delaugerre,et al.  HIV-1 resistance to first- and second-generation non-nucleoside reverse transcriptase inhibitors. , 2009, AIDS reviews.

[14]  W. Van Damme,et al.  Rapid Scale-Up of Antiretroviral Treatment in Ethiopia: Successes and System-Wide Effects , 2009, PLoS medicine.

[15]  D. Bennett,et al.  The World Health Organization's global strategy for prevention and assessment of HIV drug resistance , 2008, Antiviral therapy.

[16]  D. Bennett,et al.  World Health Organization surveys to monitor HIV drug resistance prevention and associated factors in sentinel antiretroviral treatment sites , 2008, Antiviral therapy.

[17]  T. Leitner,et al.  Introduction of HIV type 1 into an isolated population: molecular epidemiologic study from Greenland. , 2007, AIDS research and human retroviruses.

[18]  W. Sugiura,et al.  Molecular epidemiology of HIV type 1 in treatment-naive patients in north Ethiopia. , 2007, AIDS research and human retroviruses.

[19]  Z. Grossman,et al.  Threshold survey evaluating transmitted HIV drug resistance among public antenatal clinic clients in Addis Ababa, Ethiopia , 2007, Antiviral therapy.

[20]  W. Heneine,et al.  The Fitness Cost of Mutations Associated with Human Immunodeficiency Virus Type 1 Drug Resistance Is Modulated by Mutational Interactions , 2006, Journal of Virology.

[21]  Tommy F. Liu,et al.  Web resources for HIV type 1 genotypic-resistance test interpretation. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[22]  Bikram Chakraborty,et al.  Diminished Replicative Fitness of Primary Human Immunodeficiency Virus Type 1 Isolates Harboring the K65R Mutation , 2005, Journal of Clinical Microbiology.

[23]  D. Pillay.  The Emergence and Epidemiology of Resistance in the Nucleoside-Experienced HIV-Infected Population , 2000, Antiviral therapy.

[24]  D. Bennett,et al.  Darunavir: pharmacokinetics and drug interactions. , 2008 .

[25]  C. Andrzejewski,et al.  BMC Infectious Diseases , 2006 .

[26]  B. Stilwell,et al.  Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. 2006 revision. , 2006 .

[27]  J. Albert,et al.  A simple and sensitive 'in-house' method for determining genotypic drug resistance in HIV-1. , 2003, Journal of virological methods.

[28]  J Desmyter,et al.  Evaluating Clinical Isolates for Their Phenotypic and Genotypic Resistance Against Anti-HIV Drugs. , 2000, Methods in molecular medicine.